Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Generation of biobetters could push out biosimilar development, says expert

The latest generation of “biobetters” which are engineered to be more effective than branded biologics are hitting the market before biosimilars and could make development of the latter pointless, an expert has said.

Related news

News in brief

Q1 revenues for Thermo Fisher’s Life Sciences Solutions business shot up 384% year-over-year in a quarter that saw the integration of Life Technologies.

The US Food and Drug Administration (FDA) has offered guidance for biologics makers as to when two mAbs (monocolonal antibodies) should be viewed as the same.

Epirus and Zalicus have agreed to merge in order to focus on the development and manufacture of biosimilars.

Aastrom Biosciences will pay Sanofi $6.5m for its cell therapy business in a deal that gives the cash strapped regenerative medicines developer three commercial products.

Global Industry News


AZ for $100bn? Pfizer could buy Azerbaijan and keep the change from

With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, brings you an interactive view of what £60bn ($101bn) could get.

Big Pharma pull out and share slump won’t silence RNAi advocates from

RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs. 

Hospira announces two US recalls due to manufacturing, supplier issues from

Hospira has announced US recalls for seven lots of its propofol injection and one lot of 1% Lidocaine HCI Injection due to a glass contamination.

UK generics makers and MHRA pool manufacturing knowledge from

The British Generic Manufacturers Association (BGMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) will launch a forum for the generics industry to discuss manufacturing and quality issues.

Merck & Co. contracts Catalent to make sublingual hayfever drugs from

MSD has selected Catalent to manufacture two recently approved sublingual pollen extract drugs using its Zydis formulation platform.

Novartis scoops GSK’s oncology portfolio, trades away its vaccine division from

Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.

Key Industry Events


Access all events listing

Our events, Events from partners...